Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted biologic outperform standard care for a rare blistering disease?

NCT ID NCT07769333

Disease control Sponsor: Khyber Teaching Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This trial compares two treatment approaches for moderate to severe pemphigus vulgaris, a rare autoimmune disease causing painful blisters on skin and mucous membranes. One group receives rituximab (a biologic that targets immune B-cells) plus corticosteroids, while the other gets the standard regimen of oral corticosteroids plus azathioprine. The study will track outcomes over 12 months, focusing on complete remission rates, time to disease control, relapse rates, and side effects. The goal is to see if rituximab can offer faster, more durable remission with fewer long-term steroid side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rituximab (a biological drug that depletes B-cells) combined with corticosteroids
What this could lead to
If rituximab works better, it could offer a more effective and safer treatment for pemphigus vulgaris, with higher remission rates and less steroid exposure.
What could go wrong
This is an early-phase, non-randomized study with a small number of participants, so results may not be conclusive. Rituximab can have side effects like infections or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 years. * Active moderate-to-severe pemphigus vulgaris. * Newly diagnosed disease or disease flare. * Diagnosis confirmed by biopsy and direct immunofluorescence Exclusion Criteria: * Mild pemphigus vulgaris. * Pregnancy or lactation. * Active malignancy. * Serious infection. * Severe cardiac disease. * Severe renal disease. * Severe hepatic disease. * Prior exposure to rituximab within the last 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pemphigus vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pemphigus pemphigus vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pemphigus vulgaris Rituximab (RTX)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.